Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.-Reference-Cited by-同舟云学术

Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.

Published:2012-06 Issue:8 Volume:13 Page:600-605
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Ramos-Suzarte Mayra,Lorenzo-Luaces Patricia,Lazo Nery Gonzalez,Perez Mayte Lima,Soriano Jorge Luis,Gonzalez Carmen Elena Viada,Hernadez Ivis Mendoza,Albuerne Yisel Ávila,Moreno Beatriz Paredes,Alvarez Eduardo Santiesteban,Callejo Idael Pineda,Alert Jose,Martell Juan Antonio,Gonzalez Yanela Santiesteban,Gonzalez Yulainis Santiesteban,Astudillo de la Vega Horacio,Ruiz-Garcia Erika Betzabe,Ramos Tania Crombet

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.4161/cbt.19849

Reference38 articles.

1. The global burden of cancer: priorities for prevention

2. Rising Incidence of Adenocarcinoma of the Esophagus and nGastric Cardia

3. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States

4. Chemoradiotherapy of Locally Advanced Esophageal Cancer

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Escalation in Radical Radio(chemo)therapy for Cervical and Upper Thoracic Esophageal Cancer with 3DCRT/IMRT (ChC&UES): A Multi-center Real world Study;2024-06-04

2. Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial;British Journal of Cancer;2023-10-20

3. Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study;Current Cancer Drug Targets;2023-09

4. Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma;BioMed Research International;2023-04-24

5. Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin;Journal of Oncology;2022-09-01